drugset / Trial / NCT00132730

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

NCT00132730

Phase 2 Terminated 604 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an improvement in pulmonary (lung) function, as well as symptoms, and quality of life.

Timeline

Start
2004-06-01
Primary completion
2005-08-17
Completion
2005-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-0873 Small molecule 0.75 mg Oral
Subject MK-0873 Small molecule 1.25 mg Oral
Subject MK-0873 Small molecule 2.5 mg Oral